Vanguard Group Inc. Has $244.99 Million Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Vanguard Group Inc. increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 7.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,021,230 shares of the company's stock after buying an additional 843,996 shares during the quarter. Vanguard Group Inc. owned 8.35% of Denali Therapeutics worth $244,993,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in DNLI. Wellington Management Group LLP grew its holdings in shares of Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after purchasing an additional 903,683 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Denali Therapeutics by 44.8% during the fourth quarter. Fisher Asset Management LLC now owns 792,499 shares of the company's stock worth $16,151,000 after buying an additional 245,168 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Denali Therapeutics by 13.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after buying an additional 149,939 shares during the period. Barclays PLC raised its stake in shares of Denali Therapeutics by 101.4% in the 3rd quarter. Barclays PLC now owns 255,883 shares of the company's stock valued at $7,454,000 after buying an additional 128,823 shares in the last quarter. Finally, Yiheng Capital Management L.P. lifted its holdings in shares of Denali Therapeutics by 16.7% during the 4th quarter. Yiheng Capital Management L.P. now owns 700,098 shares of the company's stock worth $14,268,000 after acquiring an additional 100,000 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several research firms recently issued reports on DNLI. William Blair reissued an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group decreased their price target on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. JPMorgan Chase & Co. cut their price objective on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. B. Riley reaffirmed a "buy" rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Finally, HC Wainwright increased their target price on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics has an average rating of "Buy" and a consensus price target of $37.57.

Denali Therapeutics Stock Down 2.8 %

DNLI stock traded down $0.36 during midday trading on Thursday, reaching $12.50. The stock had a trading volume of 1,336,004 shares, compared to its average volume of 1,075,593. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -4.53 and a beta of 1.58. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33. The business has a fifty day simple moving average of $16.74 and a two-hundred day simple moving average of $21.94.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, equities analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.